[go: up one dir, main page]

CL2015001559A1 - Dispersión solida de un modulador selectivo de los receptores de progesterona - Google Patents

Dispersión solida de un modulador selectivo de los receptores de progesterona

Info

Publication number
CL2015001559A1
CL2015001559A1 CL2015001559A CL2015001559A CL2015001559A1 CL 2015001559 A1 CL2015001559 A1 CL 2015001559A1 CL 2015001559 A CL2015001559 A CL 2015001559A CL 2015001559 A CL2015001559 A CL 2015001559A CL 2015001559 A1 CL2015001559 A1 CL 2015001559A1
Authority
CL
Chile
Prior art keywords
solid dispersion
progesterone receptors
selective modulator
modulator
selective
Prior art date
Application number
CL2015001559A
Other languages
English (en)
Inventor
Florian Battung
Jérome Hecq
Aude Colin
Pierre-Yves Juvin
Original Assignee
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47878221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hra Pharma Lab filed Critical Hra Pharma Lab
Publication of CL2015001559A1 publication Critical patent/CL2015001559A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DISPERSION SOLIDA QUE COMPRENDE UN MODULADOR SELECTIVO DE LOS RECEPTORES DE PROGESTERONA Y UN EXCIPIENTE POLIMERICO; METODO DE PREPARACION Y COMPOSICION FARMACEUTICA QUE LA COMPRENDE.
CL2015001559A 2012-12-06 2015-06-05 Dispersión solida de un modulador selectivo de los receptores de progesterona CL2015001559A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1261721A FR2999081B1 (fr) 2012-12-06 2012-12-06 Dispersion solide d'un modulateur selectif du recepteur a la progesterone
PCT/FR2013/052952 WO2014087106A1 (fr) 2012-12-06 2013-12-05 Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Publications (1)

Publication Number Publication Date
CL2015001559A1 true CL2015001559A1 (es) 2016-01-04

Family

ID=47878221

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001559A CL2015001559A1 (es) 2012-12-06 2015-06-05 Dispersión solida de un modulador selectivo de los receptores de progesterona

Country Status (19)

Country Link
US (1) US20160213684A1 (es)
EP (1) EP2928499B1 (es)
JP (1) JP2016506390A (es)
CN (1) CN105120899B (es)
BR (1) BR112015013110B1 (es)
CL (1) CL2015001559A1 (es)
CR (1) CR20150299A (es)
DO (1) DOP2015000137A (es)
EA (1) EA029701B1 (es)
EC (1) ECSP15022501A (es)
ES (1) ES2666618T3 (es)
FR (1) FR2999081B1 (es)
GE (1) GEP201706740B (es)
MD (1) MD4591C1 (es)
MX (1) MX362151B (es)
NI (1) NI201500076A (es)
PE (1) PE20151783A1 (es)
UA (1) UA115796C2 (es)
WO (1) WO2014087106A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12133911B2 (en) 2015-06-09 2024-11-05 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
CN111714444B (zh) * 2020-06-23 2022-12-20 南京海纳医药科技股份有限公司 一种醋酸乌利司他口服固体制剂及其制备方法
CN113406230A (zh) * 2021-06-17 2021-09-17 河南泰丰生物科技有限公司 一种醋酸乌利司他固体制剂溶出曲线的测定方法
WO2023033900A1 (en) 2021-09-06 2023-03-09 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI962978A7 (fi) * 1994-07-26 1997-01-20 Laboratoires Effik Kuivien lääkevalmisteiden valmistusmenetelmä ja näin saadut lääkeaines eokset
AU730216B2 (en) * 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
MX2009006912A (es) * 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
ME02548B (me) 2009-04-14 2017-02-20 Hra Pharma Lab Postupak za kontracepciju po potrebi
CN102107007B (zh) * 2011-01-28 2012-11-07 广州朗圣药业有限公司 甾体类抗孕激素组合物及其制备方法
CN102600001A (zh) * 2011-01-19 2012-07-25 国家人口计生委科学技术研究所 缓释米非司酮阴道环制剂及其应用

Also Published As

Publication number Publication date
MX362151B (es) 2018-12-24
EP2928499A1 (fr) 2015-10-14
UA115796C2 (uk) 2017-12-26
FR2999081B1 (fr) 2015-02-27
NI201500076A (es) 2015-11-13
EA201500609A1 (ru) 2015-09-30
PE20151783A1 (es) 2015-12-20
BR112015013110A2 (pt) 2017-07-11
EA029701B1 (ru) 2018-05-31
WO2014087106A1 (fr) 2014-06-12
MD4591C1 (ro) 2019-04-30
MD20150060A2 (ro) 2015-10-31
CN105120899B (zh) 2018-07-24
DOP2015000137A (es) 2015-08-31
BR112015013110B1 (pt) 2020-07-14
ES2666618T3 (es) 2018-05-07
CR20150299A (es) 2015-08-14
FR2999081A1 (fr) 2014-06-13
MD4591B1 (ro) 2018-09-30
MX2015007127A (es) 2016-04-11
JP2016506390A (ja) 2016-03-03
EP2928499B1 (fr) 2018-01-31
CN105120899A (zh) 2015-12-02
ECSP15022501A (es) 2016-01-29
US20160213684A1 (en) 2016-07-28
GEP201706740B (en) 2017-09-25

Similar Documents

Publication Publication Date Title
CL2015001559A1 (es) Dispersión solida de un modulador selectivo de los receptores de progesterona
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
CL2018000883A1 (es) Moduladores del receptor x farnesoide
PE20160506A1 (es) Anticuerpos biespecificos especificos para fap y dr5, anticuerpos especificos para dr5 y metodos de utilizacion
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
DK3377483T3 (da) N-substituerede indolderivater som pge2-receptormodulatorer
ECSP17081744A (es) Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20140479A (es) Moduladores del receptor del estrogeno y sus usos
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
GT201300196A (es) Moduladores del receptor de glucagón
CR20150457A (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
BR112015006824A2 (pt) anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CL2015002124A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
DK2922955T3 (da) Sammensætninger og fremgangsmåder til modulering af FGFR3-ekspression
BR112015030553A2 (pt) dispositivo para a aplicação de substâncias medicinais líquidas
CL2016002562A1 (es) Régimen de dosificación de liberación inmediata de moduladores s1p.
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
HRP20181596T1 (hr) Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora
GT201400067A (es) Moduladores selectivos del receptor androgeno
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
UY34911A (es) Compuestos no esteroideos moduladores del receptor de andrógeno.
GT201600252A (es) Derivados de naftiridinadiona
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
DK3035912T3 (da) Farmaceutisk sammensætning til en langvarig frigivelse af lanreotid